Adverse Effects of Amiodarone

Pathogenesis, Incidence and Management
  • Gerald V. Naccarelli
  • Robert L. Rinkenberger
  • Anne H. Dougherty
  • David M. Fitzgerald
Review Article Adverse Drug Experience Review


Amiodarone is an extremely effective antiarrhythmic agent for the treatment of both life-threatening ventricular arrhythmias and refractory supraventricular tachyarrhythmias. Subjective minor side effects are common with amiodarone but rarely require discontinuation of therapy and are often handled by dose reduction. Serious end-organ toxicity, including pulmonry fibrosis and drug-induced hepatitis, have been the most common indications for discontinuing amiodarone therapy in these patients.


Amiodarone Flecainide Pulmonary Toxicity American Heart Journal Amiodarone Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Burger A, Dinichett C, Nicod P, Jenny N, LeMarchand BP, et al. Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin and thyrotropin: a drug influencing peripheral metabolism of thyroid hormones. Journal of Clinical Investigation 58: 255–259, 1976PubMedCrossRefGoogle Scholar
  2. Greene HL, Graham EL, Werner JA, et al. Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. Journal of the American College of Cardiology 2: 1114–1128, 1983PubMedCrossRefGoogle Scholar
  3. Hamer A, Peter T, Mandel WJ, Scheinman MM, Wales D. The potentiation of warfarin anticoagulation by amiodarone and anticoagulant treatment. Circulation 65: 1025–1029, 1982PubMedCrossRefGoogle Scholar
  4. Harris L, McKenna WJ, Rowland E, Krikler DM. Side effects and possible contraindications of amiodarone use. American Heart Journal 106: 916–921, 1983PubMedCrossRefGoogle Scholar
  5. Heger JJ, Prystowsky EN, Jackman WM, et al. Amiodarone: clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. New England Journal of Medicine 305: 539–545, 1981PubMedCrossRefGoogle Scholar
  6. Heger JJ, Prystowsky EN, Miles WM, Zipes DP. Clinical use and pharmacology of amiodarone. Medical Clinics of America 68: 1339–1366, 1984Google Scholar
  7. Ingram DV. Ocular effects in long-term amiodarone therapy. American Heart Journal 106: 902–940, 1983PubMedCrossRefGoogle Scholar
  8. Kaplan LJ, Cappaert WE. Amiodarone keratopathy: correlation to dosage and duration. Archives of Ophthalmology 100: 601–620, 1982PubMedCrossRefGoogle Scholar
  9. Kerin NZ, Blevins RD, Kerner N, Faitel K, Frumin H, et al. A low incidence of proarrhythmia using low-dose amiodarone. Journal of Electrophysiology 2: 289–295, 1988CrossRefGoogle Scholar
  10. Magro SA, Lawrence EC, Wheeler SH, Krafchek J, Lin HT, et al. Amiodarone pulmonary toxicity: prospective evaluation of serial pulmonary function tests. Journal of the American College of Cardiology 12: 781–788, 1988PubMedCrossRefGoogle Scholar
  11. Marchlinski FE, Gansler S, Waxman HL, Josephson ME. Amiodarone pulmonary toxicity. Annals of Internal Medicine 97: 839–845, 1982PubMedGoogle Scholar
  12. Marcus FI. Drug interactions with amiodarone. American Heart Journal 106: 924–929, 1983PubMedCrossRefGoogle Scholar
  13. Marcus FI, Fontaine GH, Frank R, Grosgogeat Y. Clinical pharmacology and therapeutic applications of the antiarrhythmic drug amiodarone. American Heart Journal 101: 480–493, 1981PubMedCrossRefGoogle Scholar
  14. Marpinowitz U, Rabinovici J, Goldfarb D, Many A, Bank H. Interaction between warfarin sodium and amiodarone. Correspondence. New England Journal of Medicine 304: 671–672, 1981CrossRefGoogle Scholar
  15. Martino E, Safran M, Aghini-Lombardi F, et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Annals of Internal Medicine 101: 28–34, 1984PubMedGoogle Scholar
  16. McGovern B, Garan H, Kelly E, Ruskin JN. Adverse reactions during treatment with amiodarone hydrochloride. British Medical Journal 287: 175–180, 1983PubMedCrossRefGoogle Scholar
  17. McKenna WJ, Harris L, Rowland E, Whitelaw A, Storey G, et al. Amiodarone therapy during pregnancy. American Journal of Cardiology 51: 1231–1233, 1983PubMedCrossRefGoogle Scholar
  18. Meier C, Bauer B, Muller U, Ludin HP. Neuropathy during chronic amiodarone therapy. Journal of Neurology 220: 231–239, 1979PubMedCrossRefGoogle Scholar
  19. Moysey JO, Jaggarao NSV, Grundy EM, Chamberlain DA. Amiodarone increases plasma digoxin concentrations. British Medical Journal 282: 272, 1981PubMedCrossRefGoogle Scholar
  20. Naccarelli GV, Rinkenberger RL, Dougherty AH, Giebel RA. Amiodarone: pharmacology and antiarrhythmic and adverse effects. Pharmacotherapy 5: 298–313, 1985PubMedGoogle Scholar
  21. Nademanee K, Kannan R, Hendrickson J, Ookhtens M, Kay I, et al. Amiodarone-digoxin interaction: clinical significance, time course of development, potential pharmacokinetic mechanisms and therapeutic implications. Journal of the American College of Cardiology 4: 111–116, 1984PubMedCrossRefGoogle Scholar
  22. Nademanee K, Singh BN, Hendrickson JA, Reed AW, Melmed S. et al. Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. Circulation 62: 202–221, 1982Google Scholar
  23. Poucell S, Ireton J, Valencia-Mayoral P, et al. Amiodarone-associated phospholipidosis and fibrosis of the liver. Gastroenterology 86: 926–936, 1984PubMedGoogle Scholar
  24. Raeder EA, Podrid PJ, Lown B. Side effects and complications of amiodarone therapy. American Heart Journal 109: 975–983, 1985PubMedCrossRefGoogle Scholar
  25. Rakita L, Sobol SM, Mostow N, Vrobel T. Amiodarone pulmonary toxicity. American Heart Journal 106: 906–914, 1983PubMedCrossRefGoogle Scholar
  26. Rees A, Dalal JJ, Reid PG, Henderson AH. Dangers of amiodarone and anticoagulant treatment. British Medical Journal 282: 1756–1757, 1981PubMedCrossRefGoogle Scholar
  27. Rinkenberger RL, Prystowsky EN, Jackman WM, Naccarelli GV, Heger JJ, et al. Drug conversion of nonsustained to sustained ventricular tachycardia during serial electrophysiologic studies: identification of drugs that exacerbate tachycardia and potential mechanisms. American Heart Journal 103: 177–184, 1982PubMedCrossRefGoogle Scholar
  28. Rosenbaum MB, Chiale PA, Haedo A, Lazzari JO, Elizari MV. Ten years of experience with amiodarone. American Heart Journal 106: 957–964, 1983PubMedCrossRefGoogle Scholar
  29. Rotmensch HH, Belhassen B, Swanson BN, et al. Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Annals of Internal Medicine 101: 462–469, 1984PubMedGoogle Scholar
  30. Saal AK, Warner JA, Greene HL, Sears GK, Graham EL. Effect of amiodarone on serum quinidine and procainamide levels. American Journal of Cardiology 53: 1264–1267, 1984PubMedCrossRefGoogle Scholar
  31. Sanmarti A, Permanyer-Miralda G, Castellanos JM, Fos-Sala M, Galard RM, et al. Chronic administration of amiodarone and thyroid function: a follow-up study. American Heart Journal 108: 1262–1268, 1984PubMedCrossRefGoogle Scholar
  32. Sclarovsky S, Lewin RF, Kracoff O, Strasberg B, Arditta A, et al. Amiodarone-induced polymorphous ventricular tachycardia. American Heart Journal 105: 6–12, 1983PubMedCrossRefGoogle Scholar
  33. Shea P, Lal R, Kim SS, Schechtman K, Ruffy R. Flecainide and amiodarone interaction. Journal of the American College of Cardiology 7: 1127–1130, 1986PubMedCrossRefGoogle Scholar
  34. Simon JB, Manley PN, Brien JF, Armstrong PW. Amiodarone hepatotoxicity simulating alcoholic liver disease. New England Journal of Medicine 311: 167–172, 1984PubMedCrossRefGoogle Scholar
  35. Singh BN, Nademanee K. Amiodarone and thyroid function: clinical implications during antiarrhythmic therapy. American Heart Journal 106: 857–868, 1983PubMedCrossRefGoogle Scholar
  36. Soussi A, Colonna D. Troubles du rythme auriculaire et amiodarone. Journal des Agreges 7: 43, 1974Google Scholar
  37. Tartini R, Kappenberger L, Steinbrunn W, Mayer UA. Dangerous interactions between amiodarone and quinidine. Lancet 1: 1327–1330, 1982PubMedCrossRefGoogle Scholar
  38. Van Roojj WJ, Van der Meer SC, Van Rayen EA, Van Zandwijk N, Darmanata JI. Pulmonary gallium-67 uptake in amiodarone pneumonitis. Journal of Nuclear Medicine 25: 211–213, 1984Google Scholar
  39. Vos AK, Van Ramstrost AGS, Grosfeld JCM, Goossens JP. A peculiar cutaneous pigmentation from Cordarone. Dermatologica 145: 297–303, 1972PubMedCrossRefGoogle Scholar
  40. Westveer DC, Gadowski GA, Gordon S, Timmis GC. Amiodarone-induced ventricular tachycardia. Annals of Internal Medicine 97: 561–562, 1982PubMedGoogle Scholar
  41. Wilson FM, Schmitt TE, Grayson M. Amiodarone-induced cornea verticillata. Annals of Ophthalmology 12: 657–660, 1980Google Scholar
  42. Zipes DP, Prystowsky EN, Heger JJ. Amiodarone: electrophysiologic actions, pharmacokinetic and clinical effects. Journal of the American College of Cardiology 3: 1059–1071, 1984PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1989

Authors and Affiliations

  • Gerald V. Naccarelli
    • 1
  • Robert L. Rinkenberger
    • 1
  • Anne H. Dougherty
    • 1
  • David M. Fitzgerald
    • 1
  1. 1.Electrophysiology Laboratory, Division of CardiologyUniversity of Texas Medical School at HoustonHoustonUSA

Personalised recommendations